Significance
Myosin-binding protein-C (MyBP-C) is a thick filament regulatory protein found exclusively in the C-zone of the A-band in the sarcomeres of vertebrate striated muscle. Cardiac, slow skeletal, and fast skeletal MyBP-C (fMyBP-C) paralogs perform different functions. All three paralogs share similar protein structures but likely differ substantially in terms of expression and function, which may serve the distinct physiologies of fast and slow muscle fibers. However, the functional role of fMyBP-C in fast skeletal muscle is completely unknown. Genetic mutations in human fMyBP-C lead to skeletal myopathies. In this study, we used knockout mice to define the molecular basis for fMyBP-C paralog diversity. We demonstrate that fMyBP-C modulates the speed and force of fast skeletal muscle contraction.
Keywords: MYBPC2, fMyBP-C, skeletal muscle, distal arthrogryposis, contraction
Abstract
Fast skeletal myosin-binding protein-C (fMyBP-C) is one of three MyBP-C paralogs and is predominantly expressed in fast skeletal muscle. Mutations in the gene that encodes fMyBP-C, MYBPC2, are associated with distal arthrogryposis, while loss of fMyBP-C protein is associated with diseased muscle. However, the functional and structural roles of fMyBP-C in skeletal muscle remain unclear. To address this gap, we generated a homozygous fMyBP-C knockout mouse (C2−/−) and characterized it both in vivo and in vitro compared to wild-type mice. Ablation of fMyBP-C was benign in terms of muscle weight, fiber type, cross-sectional area, and sarcomere ultrastructure. However, grip strength and plantar flexor muscle strength were significantly decreased in C2−/− mice. Peak isometric tetanic force and isotonic speed of contraction were significantly reduced in isolated extensor digitorum longus (EDL) from C2−/− mice. Small-angle X-ray diffraction of C2−/− EDL muscle showed significantly increased equatorial intensity ratio during contraction, indicating a greater shift of myosin heads toward actin, while MLL4 layer line intensity was decreased at rest, indicating less ordered myosin heads. Interfilament lattice spacing increased significantly in C2−/− EDL muscle. Consistent with these findings, we observed a significant reduction of steady-state isometric force during Ca2+-activation, decreased myofilament calcium sensitivity, and sinusoidal stiffness in skinned EDL muscle fibers from C2−/− mice. Finally, C2−/− muscles displayed disruption of inflammatory and regenerative pathways, along with increased muscle damage upon mechanical overload. Together, our data suggest that fMyBP-C is essential for maximal speed and force of contraction, sarcomere integrity, and calcium sensitivity in fast-twitch muscle.
Myosin-binding protein-C (MyBP-C) is a thick filament-associated protein expressed in striated muscle. Initially discovered in skeletal muscle (1), three paralogs of MyBP-C, encoded by different genes, have been described: slow skeletal (sMyBP-C), fast skeletal (fMyBP-C), and cardiac MyBP-C (cMyBP-C) (2). The paralogs share a conserved domain structure that consists of seven immunoglobulin (Ig), three fibronectin type 3 (FN3), proline/alanine-rich, and M domains. All paralogs localize to the C-zone within the A-band region at a periodicity of 43 nm, corresponding to the position of unlabeled native stripes (3). C-terminal regions (C8 to C10) of MyBP-C anchor it to the light meromyosin of myosin and titin, while its N terminus interacts with actin and myosin subfragment 2 (4). The importance of sMyBP-C and cMyBP-C in muscle physiology has been previously established by their structural and regulatory roles within the sarcomere, extending beyond simply regulating contractility via modulation of actin and myosin interactions. However, the roles of fMyBP-C are less clear (5, 6).
Over the last two decades, the pathophysiological function of cMyBP-C in cardiac muscle has been widely studied owing to its role in familial forms of hypertrophic cardiomyopathy (7, 8). Studies on cardiac papillary muscle indicate differences in functional responses to [Ca2+] among MyBP-C paralogs, a likely result of distinct effects on thin filament activation (9). Interest in understanding the functional roles of sMyBP-C and fMyBP-C in skeletal muscle is growing, in particular after their recent association with the development of congenital skeletal muscle diseases, including distal arthrogryposis and lethal congenital contracture syndrome 4 (10, 11). sMyBP-C is the more ubiquitous of the two paralogs and is expressed primarily in both fast and slow-twitch muscle and at low levels in atrial tissue (12). Additionally, splice variants have been described in human and mouse skeletal muscles (13, 14). In contrast, fMyBP-C has not been well studied, and its structural and functional roles in skeletal muscle remain to be elucidated. The fMyBP-C paralog is highly expressed in fast-twitch muscle (14); however, its exact expression profile has remained unclear. Intriguingly, up-regulation of its expression has been documented in failing murine hearts, suggesting that it may play a role in functional compensation (14). In a murine model of denervation-induced muscle atrophy, fMyBP-C was found to be degraded, along with myosin light chains, via a MuRF1-dependent mechanism (15). Knockdown of >50% fMyBP-C expression in zebrafish by morpholino antisense nucleotides led to the development of significant skeletal muscle atrophy and functional deficits concomitant with elevated expression of atrophy-related genes (6). However, the specific physiological roles of fMyBP-C in mammalian skeletal muscle remain unknown.
In the present study, we developed a fMyBP-C global knockout (KO) mouse model (C2−/−) to investigate the structural, functional, and physiological roles of fMyBP-C in skeletal muscle. Both in vitro and in vivo studies reveal that fMyBP-C modulates myofilament calcium sensitivity and fine-tunes actin–myosin interactions to match force production to the demands of fast-twitch skeletal muscles. In summary, our studies provide evidence that fMyBP-C regulates force, power, and contractile speed in fast-twitch muscles.
Results
fMyBP-C Ablation in Mice Does Not Cause Major Disruptions in Development.
Genetic deletion of fMyBP-C (C2−/−) was achieved by the replacement of exons 2 to 22 of the Mybpc2 gene with a neomycin cassette (Fig. 1 A and B). Homozygous C2−/− mice displayed a complete KO of fMyBP-C in both fast-type extensor digitorum longus (EDL) and slow-type soleus (SOL) skeletal muscles, compared to heterozygous (C2+/−) and wild-type (WT) controls (Fig. 1 C–F). As previously reported (14), fMyBP-C expression in SOL was extremely low in WT but completely ablated in C2−/− (Fig. 1 D and F). Interestingly, C2−/− elicited 33% higher expression of sMyBP-C in EDL but not in SOL muscles (Fig. 1 C–F). However, C2−/− mice showed no gross changes in body weight and appearance, and no differences were noted in cardiac function (SI Appendix, Table S1) or cardiac and hindlimb muscle mass between WT and C2−/− mouse groups (SI Appendix, Table S2) with no obvious increases in morbidity and mortality.
fMyBP-C KO Results in Reduced Force Generation and Contraction Speed In Vivo.
To uncover the functional role of fMyBP-C in skeletal muscle, we compared in vivo muscle performance between WT and C2−/− mice. Maximum grip strength (Table 1) and treadmill running times (SI Appendix, Fig. S1A) were significantly reduced in C2−/− mice compared to WT. Plantar flexor muscle strength, measured as maximum isometric tetanic force, was significantly reduced in C2−/− compared to WT (SI Appendix, Fig. S1B). The functional role of fMyBP-C was next evaluated in isolated intact EDL (fast-) and SOL (slow-type) muscles. In C2−/− EDL, peak isometric tetanic force (Po) and specific force (SPo) were significantly decreased compared to WT (Table 1). Force–frequency analysis indicated that the isometric tetanic force of C2−/− EDL was significantly lower at both maximal and submaximal stimulation frequencies (Fig. 2A). While no difference in the rate of contraction (+dF/dt) was observed (Fig. 2B), the rate of relaxation (−dF/dt) was significantly reduced in C2−/− EDL compared to WT over a range of stimulation frequencies (Fig. 2C). In SOL, however, Po and SPo were not significantly different between WT and C2−/− (SI Appendix, Fig. S2 A–C). Maximum isometric twitch force (Pt) of EDL and SOL was comparable in both genotypes (SI Appendix, Table S3). Next, measurements of isotonic speed of contraction were obtained in EDL and SOL muscles adjusted to optimal length (L0) and maximally stimulated at 150 Hz at 10, 20, 40, 60, and 80% of each muscle’s tetanic maximal force. The speed of EDL contraction was significantly slower in C2−/− at high relative force, 60 and 80% of Po, compared to WT, while no differences in velocity were observed at lower relative forces (SI Appendix, Fig. S1C). Intact C2−/− EDL muscles generated significantly less power than WT controls (Fig. 2D and SI Appendix, Table S4). In SOL, however, isotonic speed of contraction was similar between WT and C2−/− at all ranges of applied tension (SI Appendix, Fig. S2D). This is consistent with the very low expression of fMyBP-C in SOL muscle (Fig. 1 D–F). Collectively, these in vivo and ex vivo measurements of contractile function indicate that fMyBP-C contributes to force generation, power output, and contraction speed at high loads in fast-twitch, but not slow-twitch, muscles.
Table 1.
GS/BW (mg/g) | Po (mN) | SPo (N/cm2) | |
WT | 7.77 ± 0.16 | 335 ± 14.21 | 23.98 ± 1.20 |
C2+/− | 7.52 ± 0.14 | 307 ± 19.61 | 22.97 ± 0.69 |
C2−/− | 7.12 ± 0.23* | 276 ± 15.43* | 19.53 ± 0.59**# |
In addition to maximum grip strength (normalized to body weight [GS/BW] WT, n = 11; C2+/−, n = 11; and C2−/−, n = 12), the peak isometric tetanic force (Po) and specific force (SPo) of EDL muscle (n = 4 to 8 in each group) were significantly decreased in C2−/− groups. Both male and female mice were included for the analysis. The number in parentheses is SEM. *P < 0.05 and **P < 0.01 to WT, #P < 0.05 to C2+/−. Statistical analyses were performed in all groups by one-way ANOVA followed by Tukey’s multiple comparison test.
fMyBP-C Is Predominantly Expressed in Type IIb Fibers, while KO Does Not Alter Muscle Structure.
The expression profile of slow and fast MyBP-C in different fiber types may be related to differences in muscle function. To address this question, frozen EDL muscles were serially sectioned and immunostained with various myosin heavy chain (MHC) and skeletal MyBP-C antibodies. Interestingly, while fMyBP-C was expressed in type IIb and a few type IIx fibers (Fig. 3A), it was not detected in type I and type IIa fibers. In contrast, sMyBP-C was ubiquitously expressed across all fiber types (Fig. 3A). Therefore, fMyBP-C expression is mainly restricted to type IIb fast-twitch fibers. This expression profile of fMyBP-C was also validated by single-fiber Western blot analysis (SI Appendix, Fig. S3). The deletion of fMyBP-C slightly decreased the percentage of EDL type I fibers. However, since type I fibers comprise only 5% of fibers of this muscle, the overall distribution of other major fiber types remained unaltered (SI Appendix, Fig. S4A). In addition, the average cross-sectional area of each fiber type was similar between WT and C2−/− EDL muscle (SI Appendix, Fig. S4B). Therefore, deletion of fMyBP-C does not affect overall fiber type distribution or size.
Next, to determine whether C2−/− alters the spatial distribution and organization of sMyBP-C in the sarcomere (16), skinned EDL fibers were immunolabeled with sMyBP-C antibodies. Results showed that sMyBP-C localization, as a doublet pattern, was preserved in the C-zone between two Z-disks in the C2−/− sarcomere (Fig. 3B). The distribution of fluorescence signals and the distance between two peak signals of sMyBP-C in the sarcomere were unchanged in the C2−/− EDL fibers (Fig. 3C and SI Appendix, Fig. S5). By measuring the distance between two α-actinin bands (WT; 1.69 ± 0.02 µm versus C2−/−; 1.74 ± 0.02 µm), we confirmed no difference in sarcomere length between WT and C2−/−. The peak-to-peak distance of fMyBP-C was slightly shorter than that of sMyBP-C in WT EDL (648 ± 3 nm versus 684 ± 9 nm, P < 0.01) (Fig. 3 C and D). However, double immunostaining of sMyBP-C and fMyBP-C showed nearly complete overlap of these two paralogs (Fig. 3B). As expected, fMyBP-C was not detected in C2−/− muscle fibers (Fig. 3 B and D). Even though C2−/− increases the expression of sMyBP-C (Fig. 1 C and E), it did not result in expansion of the spatial distribution of sMyBP-C in the sarcomere. Similarly, ultrastructural electron microscopy analyses revealed that sarcomeres remained well aligned in the absence of fMyBP-C (SI Appendix, Fig. S6). The widths of the A-band, Z-disk, and M lines were not significantly different between WT and C2−/− (SI Appendix, Table S5). Overall, C2−/− had no effect on gross sarcomere organization in EDL muscle. However, a significant increase in central nucleation (CN) and embryonic MHC (eMHC)-positive fibers was observed in C2−/− EDL cross sections (SI Appendix, Fig. S7). Since CN and eMHC are often indicators of muscle regeneration and/or degeneration, these findings show that KO of fMyBP-C may cause mild chronic muscle stress and/or damage in C2−/− EDL muscles.
fMyBP-C Modulates Mobility and Ordering of Myosin Heads.
To determine the effect of fMyBP-C deletion on sarcomere dynamics, time-resolved small-angle X-ray diffraction images were collected every 20 ms from an intact EDL muscle during maximum isometric tetanic force generation (Fig. 4 A and B). The I11/I10 intensity ratio is a measure of the relative degree of association between myosin heads and thin filaments. This ratio was an approximation of linear force over the period of activated tetanic force with the slope of this relationship being significantly greater in C2−/− as compared to WT (Fig. 4C), leading to a significantly increased I11/I10 at peak force (Fig. 4D). The average change in I11/I10 from rest to peak tetanic force generation (ΔI11/I10) was twofold greater in C2−/− compared to WT EDL (2.79 versus 1.40, P < 0.01) (Fig. 4E). However, no difference was noted in I11/I10 in the resting state (noncontracting) EDL muscles between the two groups (Fig. 4D). The interfilament lattice was increased in C2−/− EDL compared to WT. This increase was significant in both intact (+0.8 nm, P < 0.05) and skinned EDL muscles (+1.5 nm, P < 0.05) (Fig. 4 F and G).
To examine the changes in myosin layer line, intensities in diffraction patterns during resting (Fig. 4A, left portion) and maximum isometric tetanic contraction (Fig. 4A, right portion) were measured. The intensity of the fourth myosin layer line (IMLL4) under resting conditions was significantly lower in C2−/− compared to WT (Fig. 4H), indicating reduced quasi-helical ordering of the myosin heads around the thick filament backbone. However, the residual IMLL4 during isometric contraction (ratio of contracting IMLL4 over resting IMLL4) was no different between the two genotypes, indicating that the relative changes in the proportion of ordered cross-bridges between rest and contraction were similar (SI Appendix, Fig. S8 A and B). In addition, fMyBP-C KO did not affect the movement of tropomyosin in the thin filaments during contraction (SI Appendix, Fig. S8C).
Ablation of fMyBP-C Results in Reduced Force Generation and Calcium Sensitivity in Single EDL Fibers.
To further examine the contribution of fMyBP-C to lattice spacing and force generation in fast-twitch EDL muscle, we compared the contractility of skinned WT and C2−/− type IIb fibers treated with dextran (3% w:v). Dextran osmotically compresses the muscle and restores in vivo lattice spacing. C2−/− muscles produced significantly less steady-state isometric force both in the absence (Fig. 5A) and presence of dextran (Fig. 5B and SI Appendix, Table S6), and this reduction extended to lower concentrations of activating Ca2+. At pCa 4.5, C2−/− muscles generated significantly less maximal force than that of WT (Fig. 5 A and C and SI Appendix, Table S6). Although dextran increased maximal force production for both WT and C2−/−, C2−/− muscles still produced significantly less (P < 0.01) maximal steady-state isometric force (Fig. 5 B and C and SI Appendix, Table S6).
Myofilament calcium sensitivity (pCa50) was significantly reduced in C2−/− compared to WT controls (Fig. 5D and SI Appendix, Fig. S9A). Although dextran increased pCa50 for both WT and C2−/−, C2−/− still showed a statistically significant decrease in myofilament calcium sensitivity (P < 0.01) (Fig. 5D and SI Appendix, Fig. S9B). We then evaluated cross-bridge kinetics by measuring the rate of force redevelopment (kTR) following a slack and restretch test. kTR at maximal steady-state isometric activation (pCa 4.5) was comparable between groups (Fig. 5E and SI Appendix, Fig. S6). However, kTR was significantly greater in C2−/− muscle at submaximal Ca2+ concentrations (pCa 5.5 to 5.2) compared to WT (Fig. 5E).
Compared to WT, C2−/− EDL muscles showed significantly less sinusoidal muscle stiffness at all levels of calcium activation in both the absence or presence of dextran (Fig. 5F and SI Appendix, Fig. S9C). Interestingly, restoration of in vivo lattice spacing with dextran resulted in a greater relative increase of force generation (Fig. 5C) and maximal sinusoidal stiffness (Fig. 5 G and H) in C2−/− EDL muscle compared to that in WT muscles. Rigor stiffness showed no significant differences between WT and C2−/− in the presence or absence of dextran (Fig. 5H). The ratio of maximal active stiffness to rigor stiffness can be used to measure the proportion of active force-producing cross-bridges (17). In C2−/− EDL muscle, this ratio is substantially reduced in both the absence (WT = 65% and C2−/− = 49%) and presence (WT = 60% and C2−/− = 51%) of dextran, indicating that C2−/− muscles have proportionately fewer force-producing cross-bridges during active contraction as compared to WT.
Molecular Compensation from the Loss of fMyBP-C.
Molecular compensatory responses of individual fast-twitch fibers in the absence of fMyBP-C were evaluated by single muscle fiber transcriptomic (RNA sequencing, or RNA-seq) analysis (18). In total, 191 differentially expressed genes (DEGs) were identified between C2−/− and WT fibers (SI Appendix, Fig. S10). Key genes which negatively regulate inflammatory responses (IFITM3 and CSF1) and actin filament polymerization (GSN, PALMD, and LMOD1) were identified among the 15 most deregulated genes in C2−/− fibers. Genes regulating muscle regeneration and differentiation (TMEM8C, PALMD, and APCDD1) were also significantly decreased, while negative regulators of muscle regeneration (PHLDA3 and METTL21C) were increased in C2−/− fiber (SI Appendix, Fig. S10A). Gene ontology enrichment analysis indicated that signaling pathways related to inflammatory responses, actin polymerization, and muscle regeneration/differentiation were significantly up-regulated in C2−/− samples (Fig. 6A and SI Appendix, Fig. S10B). Changes in the transcript levels of six different sMyBP-C variants were determined by RNA-seq in EDL fibers (SI Appendix, Fig. S11) and generally showed modest and variable differences in expression among isoforms in both WT and C2−/−, likely accounting for the effects of fMyBP-C ablation on structure and contractility.
Next, we performed global proteomic and phosphoproteomics of WT and C2−/− EDL fibers (SI Appendix, Tables S7–S9) to examine whether compensatory changes in the expression, or post-translational modifications, of sarcomeric proteins could account for the functional changes seen in C2−/− muscle (19). In addition, we measured by Western blot the phosphorylation levels of sMyBP-C at the Ser-59/Ser-62 sites (20) and phosphorylation of myosin regulatory light chain 2 (MLC2) at the Ser-16 site (21). Despite an increase in total sMyBP-C expression, no difference was seen in sMyBP-C phosphorylation levels between WT and C2−/− (SI Appendix, Figs. S12 and S13). The total MLC2 protein was significantly decreased (−26%) with no change of MLC2 phosphorylation in C2−/− EDL intact muscles (SI Appendix, Fig. S13). Interestingly, expression of the skeletal muscle stress response proteins, ankyrin repeat domain containing protein 2 (Ankrd2) and crystallin αB (Cryab), increased in C2−/− EDL. Elevated levels of these proteins were further validated by Western blot analysis (SI Appendix, Fig. S14). Lastly, comparison of RNA-seq and mass spectroscopy data revealed DEGs and differentially translated proteins in C2−/− fibers in gene clusters related to muscle contraction, inflammation, actin filament polymerization, and muscle regeneration and differentiation (Fig. 6A and SI Appendix, Figs. S15 and S16).
Maladaptation of C2−/− Muscle to Mechanical Overload.
Fast skeletal muscles normally exhibit hypertrophy in response to chronic overload (21). We compared the response of WT and C2−/− plantaris muscles (PLN) to mechanical overload, which was generated by removing synergistic muscles (the SOL and 70% of the gastrocnemius). The C2−/− PLN was significantly less hypertrophied after 2 wk of overload compared to WT PLN (Fig. 6 B and C). In addition, the number of fibers containing CN increased significantly in C2−/− PLN (Fig. 6D). Similarly, C2−/− PLN exhibited an increased number of eMHC-positive fibers (Fig. 6E) and greater area occupied by fibrotic tissue (Fig. 6F) compared to WT. Altogether, these data demonstrate that expression of fMyBP-C is vital for regeneration and proper load-induced muscle growth.
Discussion
fMyBP-C Is Essential for Generating Maximal Force in Fast Skeletal Muscles.
The fMyBP-C paralog is predominantly expressed in fast-twitch muscles, specifically within type IIb fibers, while sMyBP-C is expressed in both fast- and slow-twitch muscles (14). However, the physiological, structural, and functional roles of fMyBP-C in skeletal muscles are unknown. To define these roles, we used newly generated C2−/− mice in which fMyBP-C expression was globally ablated in all muscle types. Importantly, C2−/− was benign with no signs of excess morbidity and mortality. C2−/− EDL fibers, however, showed reduced contractility when stimulated both in vivo and ex vivo, and their hypertrophic response to mechanical overload was impaired. Furthermore, C2−/− EDL muscles contracted more slowly during isotonic contraction and generated lower maximal and submaximal forces during isometric contractions as compared to WT muscles. These findings imply that expression of fMyBP-C is critical for generating maximal force under resistance exercise, in which a greater number of cross-bridges are needed to match the increased force and power requirements. Such a role is consistent with the greater relative expression of fMyBP-C in fast-twitch (type IIb) fibers, which are activated when greater force, power output, and contraction speed are required (6). We can see parallels to these findings in zebrafish muscles, which lack fMyBP-C, correspondingly producing less maximum tetanic force (6). Similarly, 70% knockdown of sMyBP-C in mouse flexor digitorum brevis results in significantly decreased contractility and, hence, markedly reduced twitch and tetanic force and contraction velocity (22). In contrast, cMyBP-C KO results in enhanced force development (kTR) with increasing actomyosin kinetics without changing maximal force (23). The deletion of cMyBP-C in cardiac muscle induced a similar inflammatory response, also suggesting abnormal regenerative processes (5, 24). Taken together, our studies demonstrate that fMyBP-C is essential for generating maximal force in fast-twitch muscle. These findings highlight the different regulatory roles of MyBP-C paralogs in different striated muscles when considering the fundamental aspects of muscle contraction, such as thin filament activation, calcium handling, and actomyosin interaction (9).
Compensatory Responses for the Loss of fMyBP-C in Fast Skeletal Muscles.
In the present study, ablation of fMyBP-C in skeletal muscle induced an increase of greater than 30% in sMyBP-C expression without changing its phosphorylation status, suggesting that fMyBP-C and sMyBP-C transcomplementation may occur in the absence of one or the other in skeletal muscles. While sMyBP-C may partially compensate for the loss of fMyBP-C, functional data suggest that this compensation is insufficient to fully maintain the force of contraction and fully replace the function of fMyBP-C in fast-twitch muscle. We also determined that total MLC2 protein is down-regulated in C2−/− EDL muscles, most likely contributing to the observed reduction in force and speed of contraction (21). Significantly increased expression of Ankrd2 and Cryab proteins can be attributed to the secondary effects of fMyBP-C deletion, indicating elevated muscle stress and damage in C2−/− EDL (25, 26). Finally, single-fiber RNA-seq data demonstrated that tumor necrosis factor–mediated signaling pathways, negative actin polymerization, and muscle regeneration/differentiation were all significantly up-regulated, suggesting additional responses compensating for the lack of fMyBP-C beyond those from sMyBP-C. Overall, compensatory sMyBP-C up-regulation, secondary consequences of MLC2 loss, and elevated Ankrd2 and Cryab highlight the essential role of fMyBP-C in regulating maximal force and velocity of contraction under high mechanical loads in fast skeletal muscles. While it is beyond the scope of this paper, future work will undertake a systematic study using sMyBP-C, fMyBP-C, and double KO mouse models to define this compensatory activity in the context of muscle disease.
Ablation of fMyBP-C Results in Reduced Myofilament Calcium Sensitivity.
In general, MyBP-C paralogs modulate actomyosin interactions via their N-terminal regions (C1 to C2 domains) (9). Similar to the cMyBP-C null phenotype (23), fMyBP-C null myofilaments showed decreased myofilament calcium sensitivity, indicating that more calcium is required to generate half-maximum force compared to controls. Previously, we reported that the amino terminal region of fMyBP-C increases force generation and calcium sensitivity while reducing sliding velocities at high Ca2+ (9). These results demonstrate that fMyBP-C functions in a manner similar to that of cMyBP-C but not sMyBP-C. Since the amino terminus is the region with greatest divergence among MyBP-C paralogs, fMyBP-C may have evolved to optimize faster force generation at levels of intracellular calcium required to meet the demand of fast-twitch fiber contraction. Intracellular calcium in fast skeletal muscles operates over a wide dynamic range and is characterized by periods of steady nanomolar levels [Ca2+] at rest punctuated by brief bursts of high (micromolar) levels of Ca2+ in active muscles. Conversely, sMyBP-C promotes thin filament activation at low Ca2+ concentration (9). By contrast, Ca2+ changes in cardiac muscle fluctuate over a wide range of concentrations in a continuously repeating cycle. Although fMyBP-C expression is normally undetectable in cardiac muscle, it is up-regulated in hypertrophied myocytes, which must produce force against greater loads (14). Thus, different MyBP-C paralogs appear to play distinct roles in thin filament activation and myofilament regulation in order to generate rates and force of contraction appropriate for the tissues in which they are found.
Increased Myofilament Lattice Spacing and Increased Mobility of Myosin Heads but Smaller Proportion of Force-Producing Cross-Bridges in C2−/− EDL Fibers.
Compared to WT, X-ray diffraction analysis indicated that C2−/− EDL fibers had fewer myosin heads quasi-helically ordered around the thick filament backbone at rest and that a greater shift of mass takes place in the form of myosin heads toward actin during maximum isometric tetanic contraction. These differences occurred in association with a larger actomyosin lattice spacing in C2−/− muscle at rest. Computational modeling studies (27) indicate that increased lattice spacing, relative to in vivo spacing, results in less force per active cross-bridge, that is, cross-bridges become less efficient when the lattice is perturbed away from the in vivo spacing. This notion is supported by the stiffness data showing a substantial increase in the ratio of maximal active stiffness to rigor stiffness, a measure of the proportion of force-producing active cross-bridges in both C2−/− and WT in the presence of dextran where the in vivo spacing is restored (17). Larger lattice spacing by itself, therefore, can account for some fraction of the force deficit in C2−/− EDL muscle fibers. Based on our observations, we propose that fMyBP-C deletion causes dysregulation of thick filament-based activation mechanisms, increases lattice spacing, and decreases calcium sensitivity in a manner similar to that of the impact of null cMyBP-C on cardiac muscles (23, 28).
Changes in actomyosin interactions are consistent with the observed significant reduction in sinusoidal stiffness during steady-state muscle activation. Lattice spacing alone, however, is unlikely to account for the entire force deficit in C2−/− muscle. Our stiffness data indicate a substantially smaller fraction of force-producing cross-bridges in C2−/− compared to WT at all levels of calcium activation. C2−/− displayed significantly reduced maximal sinusoidal stiffness in both the absence and presence of dextran. Part of this decrease may result from the increased lattice spacing. Restoration of in vivo lattice spacing with dextran resulted in a proportionally greater increase of force generation in C2−/− muscle than that in WT. Finally, the ratio of maximal active stiffness to rigor stiffness is substantially reduced in C2−/− EDL muscle relative to WT in both the absence and presence of dextran. This is a clear indication that C2−/− has a lower proportion of force-producing cross-bridges during active contraction as compared to WT, regardless of the lattice spacing. This is likely to be the primary factor contributing to reduced force in the absence of fMyBP-C in skeletal muscle.
The lower proportion of force-producing cross-bridges could also be a result of fewer cross-bridges stereospecifically bound to actin or fewer bound cross-bridges able to efficiently produce force (27). We do not have enough information to resolve this question. Nonetheless, it is clear from the kTR, myosin layer line, and I11/I10 measurements that the deficit does not result from an inability of the heads to reach actin owing to helical ordering around the thick filament backbone; rather, the force deficit originates from altered actomyosin interactions per se.
We might ask how to reconcile the smaller fraction of force-producing cross-bridges with X-ray diffraction data indicating a greater proportion of myosin heads associated with the thin filament. Some evidence to address this question is provided by Brunello et al., who report that myosin heads in the so-called D-zones of cardiac muscle lack MyBP-C on the thick filaments (29). As such, these myosin heads are predominantly in a disordered relaxed state rather than quasi-helically arranged around the thick filament backbone, which is confined to the C-zone. This result suggests that the presence of fMyBP-C in the C-zone helps maintain the ordered arrangement in the super relaxed state. If so, a reduction in IMLL4 and an increase in I11/I10 would be expected in C2−/− muscle because myosin heads are no longer held in an ordered array near the thin filament backbone via interactions with fMyBP-C. In fMyBP-C KO, the increased density of myosin heads near actin could form weaker and more transient interactions with the thin filament at high load as occurs within the C-zone, thereby attenuating the force and velocity of contraction.
An alternative hypothesis holds that fMyBP-C helps maintain myosin attachment and/or detachment during the large step-size required for high load contraction in fast muscles. This hypothesis is supported by the increased curvature of the force–velocity relationship and significantly reduced sinusoidal stiffness during steady-state muscle activation and rigor in C2−/− EDL muscles. While the underlying mechanisms remain unclear, the inability of C2−/− EDL muscles to contract normally against high loads results in pathological remodeling when chronically overloaded, as was observed. Collectively, these results suggest that fMyBP-C fine-tunes myofilament organization in a manner that supports more rapid activation and increases tolerance to mechanical overload. Conversely, the absence of fMyBP-C disrupts this organization and hinders force generation. In addition, the finding that rate of relaxation (−dF/dt) is reduced at all stimulation frequencies in EDL muscles of C2−/− mice suggests that fMyBP-C contributes to muscle relaxation. This impairment of relaxation is not unexpected, as similar observations have been made regarding the role of cMyBP-C in cardiac muscle relaxation (30).
fMyBP-C Null Muscles Respond Weakly to Mechanical Overload.
Normally, mechanical overload on skeletal muscle induces hypertrophy and activates a compensatory program of repair and regeneration that replaces damaged fibers. These responses are impaired in the C2−/− mouse EDL, both under baseline conditions and after chronic overload. Even after modest mechanical loading consistent with daily life, C2−/− EDL muscles exhibited damage and ongoing repair/regeneration responses, and chronic overload greatly exacerbated these maladaptations. The overloading of C2−/− mouse plantaris muscle induced severe muscle damage and triggered an ongoing elevated regenerative response which, however, could not rescue the damage. In many regions, fibrotic tissue, rather than new adult muscle fibers, replaced damaged muscle. Furthermore, transcriptome analysis of single muscle fibers demonstrated activation of inflammatory and muscle degeneration pathways in the mice.
The failure to respond to mechanical overload may be directly related to the genetic deletion of fMyBP-C, or it may reflect a sensitization owing to preexisting deficits in the muscle function of C2−/− mice. While the evidence needed to resolve this question cannot be derived from the present data, we will consider it in future studies.
Conclusion
Collectively, our results indicate that fMyBP-C plays a foundational role in the proper regulation of contractile structure and function with distinct adaptations for fast skeletal muscles. fMyBP-C modulates actomyosin recruitment and cross-bridge interactions to match contractile output to demand, and this role is critical for maximal force generation. While some mechanistic questions remain to be addressed, notably, the link between force generation and molecular compensation in muscle, the current study does provide key insights into the functional roles of myosin-binding proteins in the health and disease.
Materials and Methods
Generation of Global fMyBP-C KO Mouse Model.
KO of the fMyBP-C was achieved by replacing exons 2 to 22 of the Mybpc2 gene with a Neo cassette, and the KO mouse was genotyped as described in SI Appendix.
Steady-State Force Measurements.
As previously described (31), in vivo grip strength, exercise capacity, and isometric tetanic torque of plantar flexion were measured. Ex vivo isometric force generation and isotonic speed of contraction in EDL and SOL muscle were also measured. Isometric force, sinusoidal stiffness, and force redevelopment (kTR) of intact and chemically skinned single EDL fibers were measured at 2.3 µm sarcomere length in various calcium solutions ranging from pCa 9.0 to 4.5. See more details in SI Appendix, Methods.
Molecular Analyses.
Gene and protein expressions were measured by single muscle fiber RNA sequencing, global proteomics and phosphomics, and Western blot analyses as described in SI Appendix, Methods. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRoteomics IDEntifications (PRIDE) partner repository with the dataset identifier PXD022316. RNA-seq data were deposited in the National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus database (access no. GSE160827).
Immunofluorescence, Histology, and Electron Microscopy.
Frozen sections and skinned EDL fibers (n = 3 to 4 in each group) were stained with hematoxylin and eosin and Masson’s trichrome, immunostained with specific antibodies, and examined as previously described (31). To evaluate the integrity of sarcomere structure, fixed EDL muscles (n = 3 in each group) were cut and dehydrated. After embedding in Epon, samples were sectioned (at 70 nm thick) and stained with uranyl acetate followed by lead citrate (32). Grids were examined under a transmission electron microscope.
X-Ray Diffraction Analysis.
X-ray diffraction pattern of EDL muscle was measured at rest and during isometric contraction as previously described (33). X-ray images were analyzed using the BioCAT MuscleX program suite (34).
Synergistic Muscle Ablation.
Chronic mechanical overloading was induced in both plantaris muscles by surgically removing whole SOL and 70% of the gastrocnemius muscles. Adaptation to the overloading was evaluated histologically at 2 wk following surgery.
Statistical Analysis.
All values presented as mean ± SE were compared with one- or two-way ANOVA with repeated measures, where appropriate, and the use of Bonferroni post hoc test to compare individual means.
Further experimental details are described in SI Appendix.
Supplementary Material
Acknowledgments
S.S. has received support from NIH grants R01 HL130356, R01 HL105826, R01 AR078001, and R01 HL143490 and American Heart Association 2019 Institutional Undergraduate Student (19UFEL34380251) and transformation (19TPA34830084) awards. T.S. (19POST34380448) and J.W.M. (17POST33630095) were supported with American Heart Association Fellowship training grants. R.C. was supported by NIH grants P01 HL059408, R01 AR067279, and R01 HL139883. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357 and supported by grant P41 GM103622 from the National Institute of General Medical Sciences of the NIH. We thank Dr. Aikaterini Kontrogianni-Konstantopoulos for the sMyBP-C phospho-specific antibodies and Dr. Kwangmin Choi and Dr. Arif Mohammed for their support of RNA-seq and proteomics data analyses and interpretation. Through Loyola University Chicago, Dr. Pieter de Tombe provided institutional funding support to generate C2−/− mice. We thank the Proteomic and Metabolomics Facility of Cornell University for generating the mass spectrometry data and the funding support from the HHMI Transformative Technology 2019 Program for the Orbitrap Eclipse system.
Footnotes
Competing interest statement: S.S. provided consulting and collaborative research studies to the Leducq Foundation, Red Saree Inc., Greater Cincinnati Tamil Sangam, AstraZeneca, MyoKardia, Merck, and Amgen, but such work is unrelated to the content of this manuscript.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2003596118/-/DCSupplemental.
Data Availability
Proteomics and RNA-seq data have been deposited in PRIDE, NCBI’s Gene Expression Omnibus (PXD022316; GSE160827).
References
- 1.Starr R., Offer G., Polypeptide chains of intermediate molecular weight in myosin preparations. FEBS Lett. 15, 40–44 (1971). [DOI] [PubMed] [Google Scholar]
- 2.Gautel M., Fürst D. O., Cocco A., Schiaffino S., Isoform transitions of the myosin binding protein C family in developing human and mouse muscles: Lack of isoform transcomplementation in cardiac muscle. Circ. Res. 82, 124–129 (1998). [DOI] [PubMed] [Google Scholar]
- 3.Luther P. K., et al., Understanding the organisation and role of myosin binding protein C in normal striated muscle by comparison with MyBP-C knockout cardiac muscle. J. Mol. Biol. 384, 60–72 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Flashman E., Redwood C., Moolman-Smook J., Watkins H., Cardiac myosin binding protein C: Its role in physiology and disease. Circ. Res. 94, 1279–1289 (2004). [DOI] [PubMed] [Google Scholar]
- 5.McConnell B. K., et al., Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J. Clin. Invest. 104, 1235–1244 (1999).Corrected in: J. Clin. Invest.104, 1771 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Li M., Andersson-Lendahl M., Sejersen T., Arner A., Knockdown of fast skeletal myosin-binding protein C in zebrafish results in a severe skeletal myopathy. J. Gen. Physiol. 147, 309–322 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Barefield D., et al., Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J. Mol. Cell. Cardiol. 79, 234–243 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Sadayappan S., et al., Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ. Res. 97, 1156–1163 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lin B. L., et al., Skeletal myosin binding protein-C isoforms regulate thin filament activity in a Ca2+-dependent manner. Sci. Rep. 8, 2604 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Gurnett C. A., et al., Myosin binding protein C1: A novel gene for autosomal dominant distal arthrogryposis type 1. Hum. Mol. Genet. 19, 1165–1173 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Markus B., et al., Autosomal recessive lethal congenital contractural syndrome type 4 (LCCS4) caused by a mutation in MYBPC1. Hum. Mutat. 33, 1435–1438 (2012). [DOI] [PubMed] [Google Scholar]
- 12.Dhoot G. K., Perry S. V., Expression of slow skeletal myosin binding C-protein in normal adult mammalian heart. J. Muscle Res. Cell Motil. 26, 143–148 (2005). [DOI] [PubMed] [Google Scholar]
- 13.Ackermann M. A., Kontrogianni-Konstantopoulos A., Myosin binding protein-C slow: A multifaceted family of proteins with a complex expression profile in fast and slow twitch skeletal muscles. Front. Physiol. 4, 391 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lin B., et al., Cardiac myosin binding protein-C plays no regulatory role in skeletal muscle structure and function. PLoS One 8, e69671 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cohen S., et al., During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083–1095 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li A., et al., Skeletal MyBP-C isoforms tune the molecular contractility of divergent skeletal muscle systems. Proc. Natl. Acad. Sci. U.S.A. 116, 21882–21892 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kawai M., Karam T. S., Kolb J., Wang L., Granzier H. L., Nebulin increases thin filament stiffness and force per cross-bridge in slow-twitch soleus muscle fibers. J. Gen. Physiol. 150, 1510–1522 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Song T., Sadayappan S., Fast skeletal myosin binding protein-C regulates fast skeletal muscle contraction Gene Expression Omnibus (GEO) database. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160827. Deposited 30 November 2020.
- 19.Zhang S., Fast skeletal myosin binding protein-C regulates fast skeletal muscle contraction Proteomics IDEntification Database (PRIDE). https://www.ebi.ac.uk/pride/archive/projects/PXD022316. Deposited 3 November 2020.
- 20.Ackermann M. A., Ward C. W., Gurnett C., Kontrogianni-Konstantopoulos A., Myosin binding protein-C slow phosphorylation is altered in Duchenne dystrophy and arthrogryposis myopathy in fast-twitch skeletal muscles. Sci. Rep. 5, 13235 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kampourakis T., Sun Y. B., Irving M., Myosin light chain phosphorylation enhances contraction of heart muscle via structural changes in both thick and thin filaments. Proc. Natl. Acad. Sci. U.S.A. 113, E3039–E3047 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Geist J., Ward C. W., Kontrogianni-Konstantopoulos A., Structure before function: Myosin binding protein-C slow is a structural protein with regulatory properties. FASEB J., 10.1096/fj.201800624R (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Harris S. P., et al., Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 90, 594–601 (2002). [DOI] [PubMed] [Google Scholar]
- 24.Lynch T. L. IV, et al., Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation. J. Mol. Cell. Cardiol. 102, 83–93 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fortes M. A., et al., Overload-induced skeletal muscle hypertrophy is not impaired in STZ-diabetic rats. Physiol. Rep. 3, e12457 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dimauro I., Antonioni A., Mercatelli N., Caporossi D., The role of αB-crystallin in skeletal and cardiac muscle tissues. Cell Stress Chaperones 23, 491–505 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bershitsky S. Y., et al., Muscle force is generated by myosin heads stereospecifically attached to actin. Nature 388, 186–190 (1997). [DOI] [PubMed] [Google Scholar]
- 28.Stelzer J. E., Patel J. R., Moss R. L., Protein kinase A-mediated acceleration of the stretch activation response in murine skinned myocardium is eliminated by ablation of cMyBP-C. Circ. Res. 99, 884–890 (2006). [DOI] [PubMed] [Google Scholar]
- 29.Brunello E., et al., Myosin filament-based regulation of the dynamics of contraction in heart muscle. Proc. Natl. Acad. Sci. U.S.A. 117, 8177–8186 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Toepfer C. N., et al., Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci. Transl. Med. 11, eaat1199 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Song T., et al., Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation. Skelet. Muscle 9, 4 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Reynolds E. S., The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell Biol. 17, 208–212 (1963). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Ma W., Gong H., Irving T., Myosin head configurations in resting and contracting murine skeletal muscle. Int. J. Mol. Sci. 19, E2643 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Jiratrakanvong J., et al., MuscleX: Software Suite for Diffraction X-Ray Imaging V1.13.1 (Software copyright 1999 Illinois Institute of Technology, 2018), doi: 10.5281/zenodo.1195050. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Proteomics and RNA-seq data have been deposited in PRIDE, NCBI’s Gene Expression Omnibus (PXD022316; GSE160827).